N-Acetyl-Epithalon

Dosing from the Literature

Published for longevity: nothing on the capped version; for its parent, a mouse lifespan dose of Epithalon and the 10 mg injections of Epithalamin, the extract Epithalon was modelled on, in elderly people (below). Not published: any dose of N-acetyl-Epithalon, in people or animals.

No published study gives a dose of N-Acetyl-Epithalon, measures how long it lasts, or compares it with Epithalon; a search of PubMed and Europe PMC in October 2026 found no paper on it. The first row below is what user reports describe for the capped version; the rest are the parent's published doses, each with its study.

What It Is

N-Acetyl-Epithalon — also written as Acetyl-Epitalon Amidate, Ac-Epitalon-NH₂, Ac-AEDG-NH₂, or simply "modified Epithalon" — is a chemically protected analog of Epithalon (Epitalon), the synthetic tetrapeptide (a chain of 4 amino acids) alanyl-glutamyl-aspartyl-glycine (Ala-Glu-Asp-Gly, AEDG). The parent compound Epithalon was synthesized in the 1990s based on the amino-acid composition of Epithalamin, a polypeptide complex isolated from bovine pineal (small brain gland that makes melatonin) gland that had been clinically evaluated in the Soviet Union since the late 1970s as a putative geroprotector. The N-Acetyl-Epithalon variant takes the same four-residue backbone and protects both ends of the peptide chain — the N-terminus is acetylated (an acetyl group covalently attached to the alanine alpha-amino group) and the C-terminus is amidated (the glycine carboxylate replaced with a carboxamide). The result is a peptide approximately 432 daltons in molecular weight that is chemically more peptidase-resistant than the unprotected parent Epithalon (~390 Da).

The Khavinson research program — based at the St. Petersburg Institute of Bioregulation and Gerontology of the Russian Academy of Medical Sciences and led for decades by Vladimir Khavinson, Vladimir Anisimov, and a network of long-standing collaborators — has produced more than a hundred publications across cell culture, animal models, and human elderly cohorts on parent Epithalon and the broader family of Khavinson short peptides. Their central thesis is that ultra-short bioregulator peptides (di-, tri-, and tetrapeptides derived from tissue extracts) penetrate cellular and nuclear membranes, bind specific DNA sequences in promoter regions, and modulate transcription of genes involved in tissue-specific homeostasis and aging. Epithalon has been the most extensively characterized member of this family and the prototype example of the proposed transcription-modulation mechanism.

The acetylation and amidation modifications that produce N-Acetyl-Epithalon are routine medicinal-chemistry strategies used across peptide pharmacology to improve metabolic stability. Free peptides with unprotected termini are rapidly degraded in plasma by aminopeptidases (which trim residues from the N-terminus) and carboxypeptidases (which trim from the C-terminus); blocking either end can extend plasma half-life by an order of magnitude or more. No study has measured the half-life of Epithalon (FDA briefing document, 2026) or of the capped version; that the caps make it last hours rather than minutes, allowing less frequent doses, is the sellers' claim, not a measurement.

No peer-reviewed paper on the acetyl-amidate variant appears in PubMed or Europe PMC. The compound is marketed and sold by research-peptide suppliers worldwide, and its mechanistic claims are extrapolated from the parent peptide's literature. What this page reports about what it does is therefore Epithalon's evidence, largely the Khavinson group's, and its longer action is untested.

Mechanism of Action

No study has tested N-Acetyl-Epithalon itself, so every mechanism below is the parent Epithalon's, or its source extract's, and that the caps make it last longer has not been measured. The proposed mechanisms come mostly from the Khavinson group's cell and animal work, plus one independent cell study (Araj et al. 2025):

• Telomerase (the enzyme that rebuilds chromosome caps) reverse transcriptase (hTERT) gene-expression induction — The defining mechanistic claim of the parent Epithalon literature. Khavinson, Bondarev, and Butyugov reported in 2003 (Bull Exp Biol Med, PMID 12937682) that Epithalon treatment of cultured human somatic cells (fetal fibroblasts) increased expression of the catalytic subunit of telomerase (TERT) and induced enzymatic telomerase activity in cells that were previously telomerase-negative. A 2025 independent paper (Araj et al.) revisited this question in human cell lines and reported that Epitalon increases telomere length via telomerase upregulation in normal cells and via the alternative lengthening of telomeres (ALT) pathway in cancer cell lines — adding nuance to the original model.
• Telomere length maintenance / elongation — In cultured human fetal fibroblasts (cells that build collagen), Epithalon lengthened telomeres (Khavinson et al., 2003; PMID 12937682), and treated fetal lung fibroblasts kept dividing past passage 44, while untreated cells stopped at passage 34 (Khavinson et al., 2004; PMID 15455129). The 2025 independent paper repeated the telomere lengthening in human cell lines (Araj et al. 2025); it did not test the passage limit.
• Pineal axis / melatonin secretion modulation — In old female rhesus monkeys, Epithalon raised evening melatonin and normalized the daily cortisol rhythm (Khavinson et al., 2001; PMID 11524632). In a randomized comparison of 39 elderly coronary patients with 40 controls, three years of courses of the parent extract Epithalamin normalized the daily rhythm of melatonin production (Korkushko et al., 2011; PMID 22451889).
• Antioxidant defense — In old rats, the group reported antioxidant effects for both Epithalon and Epithalamin, in some tests exceeding melatonin's, and Epithalamin also raised the expression of superoxide dismutase (SOD), ceruloplasmin and other antioxidant enzymes (Kozina, Arutjunyan, Khavinson, Arch Gerontol Geriatr 2007, PMID 17317455).
• Chromatin-binding / direct gene-expression modulation — Khavinson's broader hypothesis is that ultra-short peptides enter the nucleus, bind specific DNA sequences in gene promoters and switch transcription on or off; a binding model of the group's own found a candidate Epithalon binding sequence repeated in the promoter of the telomerase gene (Khavinson et al., 2005). Fedoreyeva, Kireev, Khavinson, and Vanyushin (Biochemistry Moscow 2011, PMID 22117547) demonstrated penetration of fluorescence-labeled short peptides into the HeLa cell nucleus and characterized in vitro specific peptide–DNA interactions, with Epithalon binding preferentially to DNA containing CNG sequences, which are targets of cytosine methylation. The 2020 Khavinson/Diomede paper in Molecules (PMID 32019204) extended this work to AEDG peptide effects on neurogenic gene expression in human gingival mesenchymal stem cells, proposing histone-binding as part of the mechanism.
• Tumor incidence in mice — In female SHR mice given Epithalon 5 days a month from 3 months of age until natural death, total spontaneous tumor incidence did not change, but leukemia was 6 times less frequent, bone-marrow chromosome aberrations fell by 17.1% and the age-related shutdown of the estrous cycle was delayed (Anisimov, Khavinson et al., Biogerontology 2003; PMID 14501183). In HER-2/neu transgenic mice, a model prone to breast cancer, it reduced the cumulative number and maximum size of mammary tumors (Anisimov et al., Int J Cancer 2002, PMID 12209581).
• Acetyl-amidate caps — Sellers market the capped version as longer-lasting than Epithalon. No study has measured the half-life of either: FDA's 2026 review found no pharmacokinetic data for Epitalon (FDA briefing document, 2026), and no paper on N-Acetyl-Epithalon appears in PubMed or Europe PMC.
• Multi-tissue gene-expression effects — DNA microarray studies of AEDG peptide effects on mouse heart tissue (Anisimov SV, Boheler, Khavinson, Anisimov VN, Bull Exp Biol Med 2002) reported modulation of multiple gene clusters, supporting the general hypothesis that the peptide acts as a transcription-modulating agent rather than a single-receptor ligand.

What the Research Shows

No published study has tested N-Acetyl-Epithalon: no paper on it appears in PubMed or Europe PMC, and what is said about it comes from sellers' marketing and from its parent. The findings below are the parent Epithalon's, or those of Epithalamin, the pineal extract Epithalon was modelled on.

• Telomerase activation in human somatic cells — The 2003 Khavinson/Bondarev/Butyugov paper (Bull Exp Biol Med, PMID 12937682) is the seminal in-vitro finding: Epithalon treatment of cultured human fetal fibroblasts induced TERT expression and detectable telomerase activity in previously telomerase-negative cells, with downstream telomere elongation. This is the single most-cited Epithalon paper and the foundation of the compound's longevity-research positioning.
• Hayflick-limit extension in fibroblast culture — Subsequent Khavinson-group work in human fetal fibroblasts reported extension of replicative capacity beyond the standard Hayflick limit with sustained Epithalon exposure — fibroblast cultures continued dividing past passage 44 versus the typical termination at passage 34 in untreated controls.
• Modern independent replication (Araj et al. 2025) — A 2025 paper revisited Epitalon in modern human cell lines and reported that the peptide increases telomere length via two mechanisms: telomerase upregulation in normal cells, and ALT (alternative lengthening of telomeres) activation in cancer cell lines. This is independent (non-Khavinson) replication of the core telomere-lengthening claim using contemporary methodology, with a nuance that suggests the ALT-activation in cancer cells specifically is a meaningful safety consideration.
• Pineal axis and melatonin restoration in aged primates — In rhesus monkeys with age-related decline of nocturnal melatonin secretion, parent Epithalon administration restored a normal circadian melatonin profile (Khavinson, Goncharova, Lapin reports). Similar findings were reported in elderly human cohorts treated with parent Epithalamin.
• Antioxidant enzyme upregulation in aged rats — Kozina, Arutjunyan, Khavinson (Arch Gerontol Geriatr 2007, PMID 17317455) reported that pineal peptide preparations (Epithalamin and Epitalon) possess antioxidant properties in aged rat tissue exceeding in some cases the ROS-scavenging effect of melatonin itself.
• Lifespan and tumors in mice — SHR mouse study — Anisimov, Khavinson, Popovich and colleagues (Biogerontology 2003) administered Epitalon (1 µg/mouse, ~30–40 µg/kg) subcutaneously on 5 consecutive days per month from age 3 months until natural death in female outbred Swiss-derived SHR mice, 54 per group. Mean lifespan did not change; the longest-lived 10% lived 13.3% longer and maximum lifespan rose 12.3%. The treated group showed delayed reproductive senescence (later age-related estrous shutdown) and 17.1% fewer bone-marrow chromosome aberrations; total spontaneous tumor incidence did not change, but leukemia was 6 times less frequent.
• Lifespan extension in Drosophila — Khavinson and colleagues reported that Epithalon added to the larval culture medium of wild-strain Drosophila melanogaster extended the lifespan of the adult flies by 11–16% in both sexes.
• Tumor-incidence reduction in transgenic HER-2/neu mice — Anisimov, Khavinson et al. (Int J Cancer 2002, PMID 12209581) reported that Epitalon administration to HER-2/neu transgenic mice (a high-incidence mammary cancer model) inhibited spontaneous mammary tumor development, possibly via downregulation of HER-2/neu mammary adenocarcinoma gene expression.
• Retinitis pigmentosa study — Parent Epithalon was studied in Campbell rats (a model of hereditary retinitis pigmentosa) and prolonged the functional integrity of the eye retina; in patients with retinitis pigmentosa at the St. Petersburg Institute, 162 examined, Epithalon injected beside the eye gave a positive clinical effect in more than 90% of treated cases (visual acuity, visual fields and the retina's electrical response), against improvement in 31.5% of cases among 46 controls on standard drugs; no randomization or blinding is described (Khavinson et al., 2002; PMID 12195242).
• Elderly cardiovascular and immune normalization — Khavinson and Morozov evaluated parent Epithalamin and Thymalin in 266 elderly subjects over a 6–8 year follow-up, reporting normalization of cardiovascular, endocrine, immune, and nervous system indices and improvement in homeostasis and metabolism (Adv Gerontol 2002, PMID 12577695; Neuro Endocrinol Lett 2003, PMID 14523363). A 15-year follow-up extension reported by the Korkushko group described continued geroprotective effects in survivors.
• Neurogenesis and stem-cell differentiation — Khavinson, Diomede, Mironova et al. (Molecules 2020, PMID 32019204) reported that AEDG peptide stimulates gene expression and protein synthesis during neurogenesis in human gingival mesenchymal stem cells, with histone-binding proposed as the mechanism. This suggests potential broader regenerative-medicine applications beyond pineal-axis modulation.

Human Data

Direct human data on N-Acetyl-Epithalon specifically (the acetyl-amidate variant) is absent from the indexed peer-reviewed literature. The relevant human evidence base is the Khavinson-group human studies of parent Epithalon and the parent extract Epithalamin, from which the acetyl-amidate variant inherits its clinical positioning. Honest framing: the human evidence is single-lineage, modest in sample sizes, and not independently replicated by western multicenter RCTs.

• Khavinson & Morozov (Adv Gerontol 2002, PMID 12577695) — Geroprotective effect of Thymalin and Epithalamin in 266 elderly and older persons, 6–8 year follow-up. Reported normalization of cardiovascular, endocrine, immune, and nervous system indices. Note: this is parent Epithalamin (the polypeptide complex), not synthetic AEDG/Epithalon.
• Khavinson, Morozov (Neuro Endocrinol Lett 2003, PMID 14523363) — "Peptides of pineal gland and thymus prolong human life." Long-form review of the same 266-subject cohort, with discussion of mortality reduction in the treated group across the multi-year follow-up. Khavinson-group authorship; not independently audited.
• Retinitis pigmentosa (Khavinson et al., 2002; PMID 12195242) — Parent Epithalon injected beside the eye, 5 µg per eye daily for 10 days, in patients aged 18–72 with retinitis pigmentosa at the St. Petersburg Institute of Bioregulation and Gerontology, 162 examined: the authors report a positive effect on visual function in more than 90% of treated cases, against 31.5% of cases among 46 controls given standard drugs. Not placebo-controlled; no randomization or blinding is described.
• Telomere length in people — None of the human studies of Epithalon that FDA's 2026 review found measured telomere length: the three it found measured melatonin output, clock genes and eyesight (FDA briefing document, 2026). The telomere findings in human cells cited on this page come from cells in culture.
• Korkushko 15-year follow-up extension (Bull Exp Biol Med 2011) — Long-form follow-up of the elderly cohort treated with peptide geroprotector(s), reporting deceleration of cardiovascular system aging, prevention of age-associated impairment of physical endurance, normalization of circadian melatonin secretion, and normalization of carbohydrate and lipid metabolism over the multi-year observation window. Khavinson-group authorship.
• N-Acetyl-Epithalon variant — direct human data — Not published in the indexed peer-reviewed literature. Use is essentially extrapolative. Claims for the capped version rest on the parent's evidence and on the untested idea that the caps make it last longer.

In sum: the parent Epithalon's own human data are three short studies, as FDA's 2026 review found them (FDA briefing document, 2026); the long mortality data tested its source extract, Epithalamin, in two studies run by Khavinson's institute and a Kyiv institute (Khavinson & Morozov, 2003). No study has given the capped version to people.

Reconstitution & Storage

Sellers list N-Acetyl-Epithalon as a freeze-dried powder in vials of 5, 10 and 20 mg, occasionally 40 mg, and reconstitution guides describe mixing it with bacteriostatic water (0.9% benzyl alcohol). No storage or stability study of the capped version was found. For the parent, supplier data cited in FDA's 2026 review list the powder as stable for 3 weeks at room temperature, with the supplier advising storage dry below −18°C, and the mixed solution as stable for 2–7 days at 4°C, or below −18°C for later use (FDA briefing document, 2026).

Units refer to standard insulin syringe (U-100): 100 units = 1.0 mL.

• Reconstitution technique — Reconstitution guides describe slowly injecting BAC water down the side of the vial (not directly onto the lyophilized cake), swirling gently rather than shaking, and letting the cake dissolve without agitation.
• Mixed vials — Seller labels advise discarding a mixed vial that turns cloudy, changes color or shows particles; no study has measured how long the capped version keeps once mixed.
• Light protection — Seller labels advise keeping vials, dry or mixed, away from direct light.
• Injection site — Practitioner reports describe rotating injection sites to limit lipohypertrophy (fatty lumps under the skin) from repeated injections.

→ Calculator — vial-to-syringe math

Side Effects & Risks

For the parent, its developers report no side effects: none in the eye study's patients, including those with a history of allergy (Khavinson et al., 2002; PMID 12195242), and none in 25 years of use of the two gland extracts, by the 2003 paper's account (Khavinson & Morozov, 2003). FDA's adverse-event database held no reports for Epitalon through December 2025 (FDA briefing document, 2026). Nothing is published on the capped version. The risks below are theoretical or untested:

• Telomerase reactivation and cancer (theoretical) — FDA's reviewers raised it for the parent: Epithalon activates telomerase and lengthens telomeres, and longer telomeres are generally associated with higher cancer risk (FDA briefing document, 2026). Telomerase is switched back on in about 90% of human cancers (Araj et al. 2025). In female SHR mice, Epithalon left total tumor incidence unchanged and made leukemia 6 times less frequent (Anisimov, Khavinson et al. 2003), and in HER-2/neu transgenic mice it reduced the number and size of mammary tumors (Anisimov et al. Int J Cancer 2002, PMID 12209581); FDA judged such mouse studies too limited to settle the question (one fixed dose, female mice only, short exposure) and found no two-year cancer study (FDA briefing document, 2026).
• Existing cancer (untested) — In two breast cancer cell lines, Epithalon lengthened telomeres through the ALT pathway, which rose only slightly in normal cells (Araj et al. 2025). No study has given Epithalon, or the capped version, to people with cancer (FDA briefing document, 2026).
• Purity and identity concerns — It is sold as a research chemical, outside the quality controls applied to approved drugs, so no regulator checks a vial's purity, its peptide content, or whether both caps (the N-terminal acetyl and the C-terminal amide) are present and complete.
• Allergic / hypersensitivity reactions — The parent's eye study reported none, even in patients with a history of allergy (Khavinson et al., 2002; PMID 12195242). FDA's reviewers raised the possibility that injected Epitalon could provoke an immune response, through aggregation or peptide impurities, and found no study that tested it (FDA briefing document, 2026). The capped version is untested.
• Drug interactions — No study of interactions with any drug was found.
• Endocrine modulation — In old female rhesus monkeys, Epithalon raised evening melatonin and restored the daily cortisol rhythm (Khavinson et al., 2001; PMID 11524632); in young monkeys it left melatonin unchanged and lowered cortisol morning and evening (FDA briefing document, 2026).
• WADA / sport-anti-doping caution — N-Acetyl-Epithalon is not specifically named on the WADA Prohibited List as of the most recent published revision. However, peptides with claims to growth-factor-like or repair-signaling activity are subject to scrutiny under broader S-class categories. The List’s S0 clause covers substances no other section names and no government has approved for human therapeutic use (WADA Prohibited List 2026).
• Pregnancy and lactation — No safety data: FDA's 2026 review found no reproductive or developmental studies of Epitalon (FDA briefing document, 2026), and nothing is published on the capped version.
• Pediatric use — No safety data, in children or adults: FDA's 2026 review found no clinical study of Epitalon's safety (FDA briefing document, 2026).
• Long-term cumulative exposure — Untested. FDA's 2026 review found no repeat-dose toxicity or two-year cancer studies of Epitalon; in the mouse lifespan study, dosing 5 days a month for life added up to at most about 22 weeks of exposure (FDA briefing document, 2026).

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for N-Acetyl-Epithalon, and no study has given it to people. The parent's human studies measured eyesight, visual fields and the retina's electrical response in retinitis pigmentosa (Khavinson et al., 2002; PMID 12195242) and clock-gene activity in the blood cells of night-shift workers (Khavinson et al., 2021); the 2003 study of the extract Epithalamin tracked immune, hormone and blood-chemistry tests, and deaths (Khavinson & Morozov, 2003).

Commonly Stacked With

No published study has given N-Acetyl-Epithalon with any other compound; no paper on it appears in PubMed or Europe PMC.

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People looking at N-Acetyl-Epithalon usually compare with these:

Next Steps

References

1. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682. (The seminal in-vitro telomerase induction finding for parent Epithalon — fetal fibroblast TERT expression and telomere elongation.)
2. Anisimov VN, Khavinson VK, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. PMID: 14501183. (108 SHR mice; 5-days-per-month subcutaneous Epitalon from age 3 months until natural death; reduced chromosome aberrations, delayed reproductive senescence, reduced spontaneous tumor incidence.)
3. Anisimov VN, Khavinson VK, Provinciali M, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Imyanitov EN, Mancini R, Franceschi C. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer. 2002;101(1):7-10. PMID: 12209581. (HER-2/neu transgenic mammary cancer model; Epitalon reduced spontaneous mammary tumor development, possibly via HER-2/neu downregulation.)
4. Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363. (Khavinson-group review of the 266-subject elderly cohort treated with Thymalin and Epithalamin over 6–8 years; reported mortality reduction and multi-system normalization.)
5. Khavinson VKh, Morozov VG. [Geroprotective effect of thymalin and epithalamin]. Adv Gerontol. 2002;10:74-84. PMID: 12577695. (Russian-language clinical assessment of geroprotective effects of the two peptide bioregulators in 266 elderly subjects; cardiovascular, endocrine, immune, and nervous system normalization.)
6. Kozina LS, Arutjunyan AV, Khavinson VK. Antioxidant properties of geroprotective peptides of the pineal gland. Arch Gerontol Geriatr. 2007;44 Suppl 1:213-216. PMID: 17317455. (Pineal peptide preparations including Epitalon possess antioxidant properties exceeding melatonin's in some assays; aged-rat tissue.)
7. Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B. AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules. 2020;25(3):609. PMID: 32019204. (AEDG peptide effects on neurogenic gene expression in human gingival mesenchymal stem cells; histone-binding proposed as the mechanism.)
8. Caputi S, Trubiani O, Sinjari B, Trofimova S, Diomede F, Linkova N, Diatlova A, Khavinson V. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol. 2019;33:2058738419828613. PMID: 30791821. (Short peptide effects on stem-cell neuronal differentiation; Khavinson-collaborator authorship.)
9. Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19830585. (Comprehensive Khavinson-group review of peptide bioregulator literature in aging research.)
10. Korkushko OV, Khavinson VK, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-369. PMID: 22451889. (Long-term follow-up extension of the Korkushko/Khavinson elderly cohort.)
11. Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Peptides: Prospects for Use in the Treatment of COVID-19. Molecules. 2020;25(19):4389. PMID: 32987757. (Khavinson-group review of short peptide bioregulator applications including AEDG / Epitalon mechanistic discussion.)
12. Anisimov SV, Bokeler KR, Khavinson VK, Anisimov VN. Studies of the effects of Vilon and Epitalon on gene expression in mouse heart using DNA microarray technology. Bull Exp Biol Med. 2002;133(3):293-299. PMID: 12360356. (DNA microarray analysis of AEDG peptide effects on mouse cardiac gene expression — supporting the transcription-modulation hypothesis.)
13. Khavinson VK, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-506. PMID: 15455129. (Parent Epithalon extension of fibroblast replicative capacity beyond the Hayflick limit.)
14. Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. PMID: 22117547. (Mechanistic demonstration of short peptide nuclear penetration and specific DNA-binding — foundation of the chromatin-binding gene-expression mechanism hypothesis.)
15. Khavinson VK, Solovyov AY, Shataeva LK. Melting of DNA double strand after binding to geroprotective tetrapeptide. Bull Exp Biol Med. 2008;146(5):624-626. PMID: 19526107. (Demonstrated DNA-melting effect of an AEDG-class tetrapeptide upon binding — biophysical basis for transcription modulation.)
16. Khavinson V, Shataeva L, Chernova A. DNA double-helix binds regulatory peptides similarly to transcription factors. Neuro Endocrinol Lett. 2005;26(3):237-241. PMID: 15990728. (Theoretical and experimental case for short peptides as transcription-factor-like DNA binders — broader Khavinson hypothesis.)
17. Anisimov VN, Khavinson VK, Mikhalski AI, Yashin AI. Effect of synthetic dipeptide Vilon (Lys-Glu) on gene expression in mice. Mech Ageing Dev. 2001;122(13):1297-1304. (Sister Khavinson short-peptide dipeptide; gene-expression effects in mice — supports the transcription-modulation paradigm extended to AEDG.)
18. Khavinson VK, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012;153(1):148-151. PMID: 22808515. (Tissue-specific differentiation effects of short peptides during cellular aging.)
19. Khavinson VK, Goncharova ND, Lapin BA. Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinol Lett. 2001;22(4):251-254. PMID: 11524632. (Aged rhesus monkey study — Epitalon restoration of disturbed neuroendocrine and circadian regulation.)
20. Araj S, et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. (2025). Independent replication of the core telomere-lengthening claim in modern human cell lines, with the mechanistic nuance that ALT pathway activation is observed specifically in cancer cells and not in normal cells.
21. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
22. Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-368. PMID: 12195242. (Parent Epithalon in people: 5 µg per eye, injected beside the eye daily for 10 days; 162 patients aged 18–72 examined, 46 controls on standard drugs. Full text read for the dose, groups and side effects.)
23. Khavinson V, Linkova N, Ivko O. AEDG Peptide Regulates the Expression of Circadian Genes Clock, Cry2, Csnk1e in Human Immune Cells. World Heart J. 2021;13(1):189-191. khavinson.info/assets/files/skan/2021-khavinson_linkova_ivko.pdf. Read October 4, 2026. (Parent Epithalon in people: 0.5 mg a day under the tongue for 20 days, in women aged 40–59 working night shifts, randomized against placebo. Full text read for the dose and groups.)
24. FDA. Evaluation of Epitalon-Related Bulk Drug Substances (Epitalon (Free Base) and Epitalon Acetate) for Inclusion on the 503A Bulk Drug Substances List. FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of July 23–24, 2026; memorandum dated May 12, 2026. fda.gov/media/193345/download. Read October 4, 2026.
25. World Anti-Doping Agency. Prohibited List 2026 (in effect January 1, 2026). S0, Non-approved substances. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf. Read October 3, 2026.

Related Research

• EpithalonPineal Tetrapeptide / Khavinson Bioregulator
• BronchogenKhavinson Bronchial Bioregulator
• CardiogenKhavinson Cardiac Bioregulator
• ChonlutenKhavinson Bronchial-Mucosal Bioregulator
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.